Neuronix Uk

A New Treatment for Alzheimer's Disease.

Neuronix has developed a new treatment for Alzheimer’s disease. This non-invasive, non-pharmaceutical treatment for patients with mild to moderate Alzheimer’s Disease is CE approved for use in Europe and is undergoing a multi-site clinical study in the United States.

This patented technology uniquely combines repetitive Transcranial Magnetic Stimulation (rTMS) with Cognitive Training and has shown strong results across 8 Clinical Trials with performance several times greater than pharmaceutical options alone. This combination induces LTP (Long-Term Potentiation), which is associated with learning and memory processes. Results have indicated measurable cognitive improvement, after just a few weeks of treatment, which has shown to last for up to one year.

Neuronix is led by a highly motivated management team and is supported by a Scientific Advisory Board of key opinion leaders in the field. Started in 2008, in Israel, Neuronix is now launching its European commercial operations and is treating patients in Israel and Europe.

Clinical trials performed at the Harvard Medical School and in Israel, showed statistically significant clinical results compared with placebo. neuroAD is CE-marked for commercial use in Europe for the treatment of Alzheimer patients. neuroAD is currently undergoing a multi-center study in the U. S. for FDA approval.